Andere Sprachen Orexo AB

Aktien

A0HG6G

SE0000736415

ORX

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:49 26.04.2024			% 5 Tage	% 1. Jan.
16.54 ^SEK	-2.71%		+0.12%	+6.99%

17.04.	Orexo verlängert den Patentschutz für sein nasales Epinephrin-Pulver OX640 in den USA	CI
02.04.	Schwedisches Unternehmen Orexo will Anleihen mit Fälligkeit 2025 vorzeitig zurückzahlen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Report from Orexo AB's annual general meeting, 26 April 2024	26.04.
Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	17.04.
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US	17.04.
Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	17.04.
Sweden's Orexo Set for Early Redemption of Bonds Due 2025	02.04.
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled	02.04.
Orexo publishes the Annual and Sustainability Report for 2023	28.03.
Orexo AB Announces Board Resignations	22.03.
Correction: Notice of Annual General Meeting of Orexo	15.03.
Notice of Annual General Meeting of Orexo	15.03.
Orexo Issues SEK500 Million Social Bonds, Closes Tender Offer	14.03.
Orexo Issues Senior Secured Callable Floating Rate Social Bonds of SEK 500 Million and Announces Results of the Tender Offer for Its Existing Bonds	13.03.
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds	13.03.
Orexo Plans SEK500 Million New Social Bond Issuance, Tender Offer	08.03.
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds	08.03.
Orexo strengthens its sustainability work by establishing a social financing framework	08.03.
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	12.02.
Orexo and Sobi agree to advance feasibility study with AmorphOX	12.02.
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	12.02.
Orexo Interim Report Q4 2023, incl. Full Year Report	08.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Orexo AB

Aktien

A0HG6G

SE0000736415

ORX

Andere Sprachen

Filter